Sofinnova Ventures Adds Seasoned Chief Executive Bill Ringo to the Life Science Team

New Executive-in-Residence Appointment Key to Guiding Start-up Companies to

Rapid Success

May 08, 2007, 01:00 ET from Sofinnova Ventures

    SAN FRANCISCO, May 8 /PRNewswire/ -- Sofinnova Ventures, a venture
 capital firm investing in early-stage life science and information
 technology companies, today announced the addition of industry veteran Bill
 Ringo to its life science team. In his role as Executive-in-Residence, Bill
 will apply his experience to help start new pharmaceutical companies and
 guide existing companies and their management teams. The
 Executive-in-Residence program is one of the resources Sofinnova Ventures
 employs to steer start-ups to success.
     "Bill has had a long relationship with Sofinnova through his
 involvement with the companies we have invested in, and we are thrilled to
 have him join us on a formal basis," said Jim Healy, MD, Ph.D., and General
 Partner of Sofinnova Ventures. "Our portfolio companies and their
 management teams will reap the benefits of Bill's personal experience in
 launching products and building companies that feature outstanding product
 development, commercial, and operational expertise. Bill has a wealth of
 knowledge in working in both large pharmaceutical companies and
 biotechnology companies, and is a major asset to Sofinnova's team and our
 focus on financing spin outs."
     New Executive-in-Residence Appointment
     Bill Ringo has 35 years of experience in building compelling companies
 developing new therapeutics for the treatment of life threatening diseases.
 Bill is the former President and Chief Executive Officer of Abgenix, Inc.,
 which sold for $2.7 billion to Amgen in April 2006. Abgenix focused on
 developing human antibodies as agents to treat severe diseases such as
 cancer. Vectibix, developed to treat colorectal cancer, was Abgenix's first
 product launched by Amgen in 2006. Bill also serves as Chairman of the
 Board of Directors at Intermune, a biopharmaceutical company focused on
 developing and commercializing innovative therapies in pulmonology and
 hepatology. From June 2003 to September 2003, he also served as Intermune's
 interim President and CEO. Prior to these positions, Bill worked at Eli
 Lilly & Company and served in various capacities including: Product Group
 President, Oncology and Critical Care Products from June 1999 until his
 retirement in February 2001; President of Internal Medicine Products from
 January 1998 until June 1999; and President of Eli Lilly's Infectious
 Diseases Business Unit from September 1995 until January 1998.
     Bill is a member of the Board of Directors of Inspire Pharmaceuticals,
 Allos Therapeutics, and Portola Pharmaceuticals. He holds a B.S. and an
 M.B.A. from the University of Dayton.
     About Sofinnova Ventures
     Founded in 1974, Sofinnova Ventures is a leading venture capital firm
 specializing in spin offs and emphasizing a diversified investment strategy
 through the financing of early stage companies in the life science and
 information technology sectors. Sofinnova's mission is to create value by
 providing entrepreneurs with the resources, experience and networks
 necessary to turn their ideas into profitable businesses. For more
 information, visit

SOURCE Sofinnova Ventures